Drug
Pucotenlimab clinical trials
Also written HX008.
- studies test it
- 41
- open now
- 30
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the pucotenlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- HX008
- 12
Studies by the year they started
41 studies that test it; most in 2026 (17)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 34
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 27
Taizhou Hanzhong biomedical co. LTD (8) · Sun Yat-sen University (8) · Lepu Biopharma Co., Ltd. (3) · Fudan University (2) · Sir Run Run Shaw Hospital (2) · Jiyan Liu (2) · Tongji Hospital (2) · West China Second University Hospital (1)
Often tested with
Tested in the same studies.
Becotatug vedotin (17) · Lenvatinib (3) · Donafenib (1) · Folfox protocol (1) · Bevacizumab (1) · Oxaliplatin (1) · Trifluridine tipiracil drug combination (1) · CAPOX Regimen (1)
Studies
Open first, then newest update. How each study uses pucotenlimab is read from its arms, and is right about nine times in ten.
Testing it · 41
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT07884188Written as Pucotenlimab
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07448142Written as Pucotenlimab
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT05688605Written as MRG003+HX008
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT06976190Written as MRG003 + Pucotenlimab
- Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07766889Written as Pucotenlimab
- Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07767266Written as Pucotenlimab plus Becotatug Vedotin
- Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingPhase 2Sun Yat-sen UniversityNCT07750067Written as Pucotenlimab
- EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingPhase 2Jiyan LiuNCT07518979Written as Pucotenlimab
- Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingPhase 2Tongji HospitalNCT06192797Written as Lenvatinib plus pucotenlimab
- Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingPhase 2Tianjin Medical University Second HospitalNCT07712029Written as Pucotenlimab
- Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell CarcinomaRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07665190Written as Becotatug Vedotin and Pucotenlimab
- Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2West China Second University HospitalNCT07692334Written as Pucotenlimab
- Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase IINot yet recruitingPhase 2HuiKai LiNCT07649980Written as Pucotenlimab
- Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07627321Written as Pucotenlimab
- Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07589049Written as Pucotenlimab
- Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Not yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07545083Written as MRG003+Pucotenlimab
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT06959108Written as Pucotenlimab
- MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell CarcinomaRecruitingPhase 1Jiyan LiuNCT07054307Written as HX008
- MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical TrialNot yet recruitingPhase 2West China HospitalNCT07381699Written as Becotatug Vedotin and Pucotenlimab
- Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07394244Written as Pucotenlimab
See all 41 studies that test pucotenlimab →
Given in every arm · 8 — pucotenlimab is usual care beside what is tested
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingPhase 2Huashan HospitalNCT07844551Written as Pucotenlimab
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT07479485Written as Pucotenlimab
- A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07707167Written as Pucotenlimab
- Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Lepu Biopharma Co., Ltd.NCT07586124Written as Pucotenlimab Injection
- Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR MutationsNot yet recruitingPhase 2/3Sir Run Run Shaw HospitalNCT07598318Written as Pucotenlimab
- Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07524413Written as Pucotenlimab
- The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort StudyRecruitingPhase 2Ji DongmeiNCT07464366Written as Pucotenlimab
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownPhase 2Taizhou Hanzhong biomedical co. LTDNCT04741165Written as HX008
Codes
What other systems call pucotenlimab · ClinicalTrials.gg INT016225
- UNII (FDA) CGA81G3KR5PUCOTENLIMABOne source FDA
- NCI Thesaurus C160717PucotenlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CGA81G3KR5 | PUCOTENLIMAB | One source FDA |
| NCI Thesaurus | C160717 | Pucotenlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.